AstraZeneca’s FluMist: Self-Administered Flu Vaccine Approved

AstraZeneca (GB:AZN) has released an update.

AstraZeneca has announced the FDA approval of FluMist, the first self-administered, needle-free nasal spray influenza vaccine for adults and children in the US, aiming to increase influenza protection amid declining vaccination rates. The vaccine can be self-administered by adults up to 49 years old or by caregivers for those aged 2-17, with the option to have it delivered directly to homes through an online pharmacy service. This approval represents a significant advancement in making influenza vaccination more accessible outside traditional healthcare settings.

For further insights into GB:AZN stock, check out TipRanks’ Stock Analysis page.